Skip to main content
Signal8

Jaguar Health, Inc. (JAGX)

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Jaguar Health, Inc. logo

Jaguar Health, Inc.

NASDAQ:JAGXHealthcare
-1.68%$0.3799
CLOSED
AH$0.3704-2.50%vs close
Mkt Cap$5.07M
EV-
Float–
O/S13.35M
VOL542K sh
$ Vol$196K
RVOL0.63×
Inst Own0.1%
Net Cash/Sh-
Dilution
Jaguar Health, Inc. logoNASDAQ:JAGXClosed$0.3799-1.68%
Short interest (FINRA)
Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
Oct 30 (19d)
200.8K
Oct 30 (19d)prev 140.6K▲ 42.8%
1.00
Oct 30 (19d)prev 1.00– 0.0%
Borrow (IBKR)

The cost to borrow JAGX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
35.7%
Nov 17 (1d)prev 33.6%▲ 2.1 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

21.4K
Oct 29 (20d)prev 30.2K▼ 29.2%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 2026200.8K sh
Oct 15, 2026140.6K sh
Sep 30, 202684.2K sh
Sep 15, 202621.7K sh
Aug 31, 202616.1K sh
Latest fails to deliver
DateShares failed
Oct 29, 202621.4K sh
Oct 28, 202630.2K sh
Oct 27, 202636.5K sh
Oct 23, 202615 sh
Oct 22, 20262.8K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 17
Latest sessions
DateReported short
Nov 17, 202635.7%
Nov 16, 202633.6%
Nov 13, 202657.4%
Nov 12, 202633.5%
Nov 11, 202643.6%
91-session median 50.1%mean 46.5%range 5.1–82.9%

130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for JAGX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 200,775 JAGX shares were sold short (1.00 days to cover).